KYRON, INC.

PALO ALTO, CA · Founded 2013 · CIK 0001588922 · Biotech

Glycan-modified protein therapeutics platform

kyron.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.0M
1 Form D · Oct 2013
156 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1816Pupil Bio, Inc.—$500K
1817Hapten Sciences, Inc.—$2.7M
1818REVIVA PHARMACEUTICALS HOLDINGS, INC.——
1819KYRON, INC.—$3.0M
1820MBQ PHARMA INC.—$4.2M
1821NEUROPATHIX, INC.—$1.3M
1822CUMBERLAND PHARMACEUTICALS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • ARNOLD MILSTEINDirector
  • LOUIS MONIERDirector · Executive Officer
  • TAMMY TOMPKINSDirector

Patents

USPTO · 0 granted of 2
  • System for Generating and Updating Treatment Guidelines and Estimating Effect Size of Treatment Stepsapplication
  • System For Generating And Updating Treatment Guidelines And Estimating Effect Size Of Treatment Stepsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.